Tick-Borne Disease Panel by PCR, Blood
Also known as: TICKPCR
Use
This test is the preferred panel for diagnosing possible tick-borne diseases such as Anaplasmosis, Ehrlichiosis, or Babesiosis during the acute phase of the disease. By identifying the pathogens responsible for these diseases through PCR, clinicians can make informed decisions for treatment and management, reducing the risk of complications associated with these infections.
Special Instructions
Not provided.
Limitations
The test is developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration (FDA). A negative result does not rule out the presence of PCR inhibitors in the patient specimen or that the test-specific nucleic acid is present in concentrations below the level of detection. It is essential that the sample is correctly collected and transported to avoid false-negative results due to improper handling or storage.
New York Approved
Methodology
PCR-based (Qualitative PCR)
Biomarkers
LOINC Codes
- 30039-2 - A phagocytoph DNA Bld Ql NAA+probe
- 27994-3 - E chaffeensis DNA Bld Ql NAA+probe
- 48865-0 - E ewingii DNA Spec Ql NAA+probe
- 48866-8 - Ehrlichia DNA Spec Ql NAA+probe
- 88233-2 - Babesia DNA Bld Ql NAA+probe
- 21089-8 - B microti DNA Bld Ql NAA+probe
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
1 mL
Minimum Volume
0.6 mL
Container
Lavender (EDTA) or Pink (K2EDTA)
Causes for Rejection
Serum, plasma, and heparinized specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 24 hours |
| Refrigerated | 1 week |
| Frozen | 1 week |
Other tests from different labs that may be relevant